IPP Bureau
UK MHRA approves aumolertinib to treat non-small cell lung cancer
By IPP Bureau - June 05, 2025
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Sanofi exercises license extension option to Nurix’s STAT6 program
By IPP Bureau - June 04, 2025
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Amyris expands precision fermentation line in Brazil
By IPP Bureau - June 04, 2025
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
By IPP Bureau - June 04, 2025
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Biocon gets approval for diabetes drug Liraglutide in India
By IPP Bureau - June 03, 2025
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
By IPP Bureau - June 02, 2025
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
By IPP Bureau - June 02, 2025
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer
By IPP Bureau - June 02, 2025
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Keytruda plus Trodelvy reduced risk of disease progression by 35% V/s Keytruda plus cchemothrapy in first-line PD-L1+ TNBC
By IPP Bureau - June 02, 2025
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4
By IPP Bureau - June 02, 2025
Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows
By IPP Bureau - June 02, 2025
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
